OSLO
Asset Logo

Oncosil Medical Ltd

πŸ‡¦πŸ‡Ί ASX

Compare
Add to watchlist
πŸ‘‘ Overview

πŸ“ˆ Performance

πŸ’΅ Cost

πŸ€“ Advanced

πŸ‘¨β€πŸ‘©β€πŸ‘§β€πŸ‘¦ Community

πŸ“ˆ

N/A
Annual Growth

5 years average annual growth

πŸ’΅

$ 500
Minimum Order

Due to regulatory requirements

🌏

0
Pearlers Invested

Since January 2020

πŸ‘‘ Overview

Key information
πŸ”Ž Fund Overview

Oncosil Medical Ltd - Option Expiring 30-Apr-2027

πŸ“ˆ Performance

Price History

N/A

1M

All Time

Graph

Table

Unsure how much or often to invest?
πŸ—“οΈ Investing frequency calculator

Determine the investment frequency needed to reach your goals

Try it out β†’
πŸ’΅ Investing amount calculator

Determine the recurring investment needed to reach your goals

Try it out β†’
⏱️ Investing duration calculator

Determine how long you will need to invest to reach your goals

Try it out β†’

πŸ’΅ Costs

πŸ’΅

6.50 AUD*
Purchase Fee

*$5.50 with Pearler Prepay

πŸ’Ό

N/A
Management Fee

Included in unit price, not charged by Pearler

πŸ’Έ

Want to know the long term costs?
Calculate the historic long term costs to hold your investments
πŸ’Έ Net fee calculator

πŸ€“ Advanced information

Technical Info

πŸ’° Price*

$0.00

*Price may be up to 24 hours old

πŸ‘©β€πŸ‘©β€πŸ‘¦ Community Insights

How our community is investing

🌏 Pearlers invested in OSLO

0

πŸ“Š Total Capital Earnings

N/A

πŸ”ƒ Average investment frequency

N/A

πŸ’΅ Average investment amount

N/A

⏰ Last time a customer invested in OSLO

N/A
OSLO investor breakdown
πŸ’΅ Income of investors

More than 200k

150k - 200k

100k - 150k

50k - 100k

Less than 50k

πŸ‘Ά Age of investors

18 - 25

26 - 34

35 - 90

πŸ™‹ Legal gender of investors

Female

Male

Pearlers who invest in OSLO also invest in...

Want more shares? Try these...

Oncosil Medical Ltd

OSLOB

πŸ“Š Share price

$0.00 AUD
Find Out More

Osmond Resources Ltd. is an early-stage mineral exploration and development company, which engages in the discoveries for gold, nickel, copper, and rare earth elements within the prospective Fowler Domain and Nuyts Domain, both within the Gawler Craton in South Australia as well as western Victoria. The company is headquartered in Melbourne, Victoria. The company went IPO on 2022-04-22. The firm's projects include Salt Wells Project, Iberian One Project, Yumbarra Project, Fowler Project, Coorabie Shear Zone Project, Tallacootra Project and Sandford Project. The Salt Wells Project is located in Churchill County, Nevada, United States. The Salt Wells Project consists of approximately 276 mineral claims, covering an area of 36 square kilometers (km2). The firm's Australian Projects (Yumbarra Project, Fowler Project, Coorabie Shear Zone Project, Tallacootra Project and Sandford Project) are focused on exploration for gold, nickel, copper and rare earth elements (REE) within the highly prospective Fowler Domain and Nuyts Domain, both within the Gawler Craton in South Australia and western Victoria. The Iberian One Project is located in Spain.

πŸ“Š Share price

$0.42 AUD

⛏️ MINING

Orpheus Uranium Ltd. engages in the exploration and development of minerals including gold and copper. The company is headquartered in Adelaide, South Australia. The firm is focused on uranium exploration in the two jurisdictions of Australia that permit uranium mining, South Australia and the Northern Territory. In South Australia there are five key project areas: Frome, Mundaerno, Radium Hill South, Cummins and Marree. In the Northern Territory there are four key project areas: Mount Douglas, Woolner, Alligator Rivers Uranium Field and South Alligator Valley Mineral Field. Its other projects include Higginsville, Kroombit, Aroona, Lumwana West, Kamapanda, Kalaba East, Musangila, and others. The Frome project comprises four exploration licenses covering a combined area of 3,037 square kilometers, located in the Frome Embayment of South Australia. The Mundaerno project comprises one exploration license application, EL 6958, which comprises two blocks in the Southern Curnamona Province of South Australia.

πŸ™Œ Performance (5Yr p.a)

107.27%

πŸ“Š Share price

$0.04 AUD

⛏️ MINING

OncoSil Medical Ltd. develops and commercializes neurology services, including those for pancreatic cancer. The company is headquartered in Macquarie, New South Wales. The company went IPO on 2005-08-15. The firm is focused on the development and commercialization of its lead product candidate, the OncoSil localized radiation therapy for the treatment of pancreatic and distal cholangiocarcinoma. The firm has developed a cancer treatment device, the OncoSil brachytherapy device, which is a critical component of a brachytherapy treatment for locally advanced unresectable pancreatic cancer. The OncoSil device delivers a targeted intratumoral placement of Phosphorous-32 (32P) in the treatment of locally advanced unresectable pancreatic cancer. The OncoSil device has received a device designation in the European Union, United Kingdom and United States for the treatment of locally advanced unresectable pancreatic cancer in combination with chemotherapy.

πŸ™Œ Performance (5Yr p.a)

-18.54%

πŸ“Š Share price

$0.01 AUD

πŸ”­ LIFE SCIENCES TOOLS & SERVICES

Compare
Add to watchlist